New hope for lymphoma patients: drug combo aims to boost chemo
NCT ID NCT07588698
First seen May 17, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study tests whether adding the drug epcoritamab to standard chemotherapy (R-CHOP) is safe and effective for people newly diagnosed with aggressive B-cell non-Hodgkin lymphoma. About 20 adults will receive the combination treatment. The main goal is to check for side effects like cytokine release syndrome, and to see how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zuckerberg San Francisco General
San Francisco, California, 94110, United States
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.